2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
10.11106/ijt.2023.16.1.32
- Author:
Hyun Kyung CHUNG
1
;
Eu Jeong KU
;
Won Sang YOO
;
Yea Eun KANG
;
Kyeong Jin KIM
;
Bo Hyun KIM
;
Tae-Yong KIM
;
Young Joo PARK
;
Chang Ho AHN
;
Jee Hee YOON
;
Eun Kyung LEE
;
Jong Min LEE
;
Eui Dal JUNG
;
Jae Hoon CHUNG
;
Yun Jae CHUNG
;
Won Bae KIM
;
Ka Hee YI
;
Ho-Cheol KANG
;
Do Joon PARK
Author Information
1. Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
- Publication Type:REVIEW ARTICLE
- From:International Journal of Thyroidology
2023;16(1):32-50
- CountryRepublic of Korea
- Language:English
-
Abstract:
Subclinical hypothyroidism (SCH), characterized by elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine levels, usually presents without symptoms, and is often discovered incidentally during routine blood test. The Task Force of the Korean Thyroid Association Committee of Clinical Practice Guidelines has established a guideline to evaluate and manage SCH; the guideline emphasizes the implementation of diagnostic criteria based on the TSH reference range for Koreans and focuses on the proven health benefits of levothyroxine (LT4) treatment. Based on the Korea National Health and Nutrition Examination Survey (2013-2015), serum TSH level of 6.8 mIU/L is considered the reference value for SCH. SCH can be categorized as mild (TSH 6.8-10.0 mIU/L) or severe (TSH ＞10.0 mIU/L), and patients are classified as adults (age ＜70 years) or elderly patients (age ≥70years) depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, along with the thyroid peroxidase antibody test, preferably 2-3 months after the initial evaluation. Usually, LT4 treatment is not recommended for mild SCH in adults; however, treatment is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and can be considered for coexisting dyslipidemia. LT4 treatment is not recommended for mild or even severe SCH in elderly patients, in general. Patients with SCH who receive LT4 treatment, the LT4 dosage should be personalized, and serum TSH levels should be monitored to ensure optimal LT4 dosage (dosage that is neither excessive nor insufficient). Patients with SCH who do not receive LT4 treatment require periodic follow-up at appropriate testing intervals determined by disease severity. The guideline also provides several educational points applicable in clinical settings.
